Document:

Amendment No. 1 to Supply Agreement

 Exhibit 10.13 
  
 WHENEVER CONFIDENTIAL INFORMATION IS OMITTED HEREIN (SUCH OMISSIONS ARE DENOTED BY AN ASTERISK *), SUCH CONFIDENTIAL INFORMATION HAS BEEN
SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. 
  
 Amendment No. 1 to Supply Agreement between Amersham Biosciences AB and Repligen Corporation dated May 26, 1999 
  
 This Amendment No. 1 to the Supply Agreement (defined below) is made, effective as of
February 3, 2005 (“Amendment Date”), by and between, 
  

	1.	Repligen Corporation having its address at 41 Seyon Street Bldg #1, Waltham, MA 02453, USA (“Repligen”), and 

  

	2.	Amersham Biosciences AB (formerly known as “Amersham Pharmacia Biotech AB”), a GE Healthcare company having its address at Björkgatan 30, S-751 84 Uppsala, Sweden
(“GEHC”). 

  
 RECITALS 
  

	A.	GEHC and Repligen have entered into a Supply Agreement dated May 26, 1999, (the “Supply Agreement”) concerning the supply of certain recombinant protein ligand products to
GEHC. 

  

	B.	GEHC wishes to out-source the manufacture of a new ligand called “*” as defined below and Repligen has declared its willingness to manufacture that ligand product on
behalf of GEHC. 

  

	C.	The Parties have discussed certain supply security aspects in relation to all products supplied under the Supply Agreement. 

  
 Considering the above and in consideration of the mutual covenants contained in this
Amendment No. 1, the Parties have entered into the following amendment to the Supply Agreement. 
  
 AMENDMENT 
  

	1.	Definition of product and specifications for * 

  

	1.1.	Upon completion of the TTP as defined below in this Amendment No. 1, the term “Biotech rPA” in Section 1(b) of the Supply Agreement shall be deemed to include *.

  

	1.2.	The specifications for * as attached hereto as Appendix 1 shall form part of “Biotech Specifications” in Section 1(c) of the Supply Agreement. 

  

	*	CONFIDENTIAL TREATMENT REQUESTED 

	2.	Technology Transfer 

  

	2.1.	The Parties have agreed to conduct a Technology Transfer Program (“TTP”) as set forth in the tentative plan in Appendix 2 hereto with the objective to transfer from GEHC
the manufacturing method for * to Repligen. Upon the Amendment Date the parties shall use their respective best efforts to agree on a detailed project plan for the TTP as soon as possible. Each party agrees to use all reasonable efforts to fulfill
its part of the TTP in order to complete the transfer not later than by December 31, 2005. The TTP will start as soon as technically possible following the Amendment Date and not later than 30 days following GEHC’s written notice to Repligen.

  

	2.2.	The Process Technology relating to *, including any related intellectual property rights, whether generated before or during the TTP shall be the sole property of GEHC. Such Process
Technology shall be deemed as confidential information under the Confidentiality Agreement. Repligen is hereby granted a right to use Process Technology relating to * only for the purpose of manufacturing it for supply to GEHC under this Agreement.

  

	2.3.	Any possible development work carried out by Repligen in connection with the TTP shall be subject to a separate agreement. For avoidance of doubt the TTP as defined in Appendix 2
does not include any development work. 

  

	2.4.	The parties have agreed to share costs incurred in connection with the TTP in accordance with the following principles. 

  

	 	a)	Each party shall carry its own costs in connection with the TTP unless otherwise agreed. 

  

	 	b)	Chromatography equipment purchased by Repligen from GEHC will be priced according to the terms of the Manufacturing Transfer Agreement, made by and between the parties on December
17, 1998, and subject to payments in * equal annual installments each of * of the list price, whereof the first shall be paid within 30 days from delivery and the remaining on the * following anniversaries hereof. 

  

	 	c)	The initial supply of chromatography media for the first fill of each column and the first fill of hollow fiber cartridges required for the TTP shall be supplied by GEHC *.
Following the first fill, media, hollow fiber cartridges and other consumables will be offered on the same terms as set forth in Section 16(e) of the Supply Agreement. 

  

	 	d)	Upon receipt of invoice, GEHC will pay * for delivery of each development lot meeting the specifications and the same sum for delivery of each validation lot approved according to
the validation specification limits. The price is based upon a * fermentation scale. The parties acknowledge that the purification lot size for lots produced during the TTP shall not exceed *. The parties shall use all reasonable efforts to have *
full scale validation lots to be completed and validated by GEHC by December 31, 2005. This fixed price for maximum * lots shall be 

  

	*	CONFIDENTIAL TREATMENT REQUESTED 

 inclusive of all costs incurred by Repligen in the course of the TTP and the operation of the validation
lots. In the event that the parties agree to conduct fewer than * development lots, Repligen will be paid a bonus of * for each development lot not conducted. In the event that GEHC requests fewer than * development lots and, as a result, more than
* validation lots are required to achieve full validation, GEHC agrees to pay Repligen * for each additional validation lot meeting the same requirements as set forth above, which is required for full validation. 
  

	2.5.	GEHC shall have the right to terminate the TTP without cause during the period prior to completion of the TTP upon written notice to Repligen. In such event GEHC shall compensate
Repligen for all verified reasonable direct costs incurred in connection with the TTP as per the date of termination. In the event that the TTP is terminated, the Amendment No. 1 to the License Agreement dated May 1, 1999 between Repligen and
Amersham Pharmacia Biotech AB (the “License Agreement”), made and entered into by the parties separately from this Amendment No. 1 but as of the Amendment Date, shall terminate and be of no further force or effect as specified in Section
2.4 of Amendment No. 1 to the License Agreement. 

  

	3.	Manufacturing 

  

	3.1.	After the validation has been completed according to the TTP Repligen shall manufacture and supply * in accordance with the validated and documented manufacturing process
(“Documented Process”). Repligen shall be responsible for documenting the manufacturing process according to industry standard. 

  

	3.2.	Repligen shall document and GEHC shall have access to all written manufacturing know-how relating to any of the Articles. GEHC shall have the right to carry out an annual quality
assurance audit of any such documents with 30 days prior notice. 

  

	3.3.	Repligen may make minor changes, i.e. those not requiring validation, to the Documented Processes with the prior approval of GEHC. Either party may suggest a major process change
and, by mutual written agreement, such major change will be made, validated, and incorporated into the Documented Process. If a major process change suggested by GEHC results in a significant yield improvement, then the price per gram shall be
decreased on the basis that * of the savings shall lead to reduced price and * to higher margin for Repligen. This allocation is based on the assumption that Repligen shall be compensated for its costs in connection with any agreed development work
on a * basis. Sharing of savings from yield improvements resulting from a major process change suggested and paid for by Repligen shall be applied in a reciprocal fashion, i.e. * to price reduction and * to Repligen’s margin. Save for the
foregoing the relevant provision of Section 2 in the Supply Agreement shall apply to process changes. 

  

	4.	Purchase of Biotech rPA/new Protein A based recombinant ligands 

  

	4.1.	The parties agree that upon completion of the TTP, Section 3(b) in the Supply Agreement shall also apply in relation to supply of *. In addition GEHC declares its intention to use

  

	*	CONFIDENTIAL TREATMENT REQUESTED 

 Repligen as its sole supplier for rPA during the term of the Supply Agreement, so long as Repligen is
able to fulfill the following requirements: 
  

	 	a)	reliably provide acceptable quality, quantity, and timely delivery of Biotech rPA, 

  

	 	b)	maintain agreed pricing, and 

  

	 	c)	*. 

  
 Although the above statement constitutes the good faith intent of GEHC at the time of signing this Amendment any legally binding exclusive purchasing obligation of GEHC is subject to entering into separate written
agreement being in compliance with any applicable laws and regulations. 
  

	4.2.	Repligen shall have a first right of refusal to become a Preferred Supplier to GEHC of any *, provided that Repligen can meet GEHC’s requirement as regards quality, price,
volume and *. Within 30 days from receipt of GEHC’s request for offer, including relevant information on volumes, lead times and specifications, Repligen shall submit a complete written quotation to GEHC, which shall be evaluated without delay.
If such quotation is not acceptable to GEHC then it shall provide Repligen with a written explanation of what requirements are not met and Repligen shall have an opportunity to negotiate mutually acceptable terms with GEHC. If after 30 days of good
faith negotiation the parties are unable to reach mutually acceptable terms, GEHC shall thereafter be free to engage any other supplier for the subject matter specified in GEHC’s request for offer. If Repligen fails to submit a quotation then
GEHC shall be relieved from its obligations according to this paragraph in relation to the subject matter specified in GEHC’s request. 

  

	4.3.	GEHC agrees to evaluate the possibility of having Repligen as a possible supplier to GEHC of *, provided that Repligen can meet GEHC’s requirement as regards transfer costs,
customer acceptance requirements, quality, price, volume, and *. Within 60 days of a written request by Repligen, GEHC agrees to provide Repligen with such information it deems relevant to Repligen to prepare a quotation for the supply of such *.
GEHC agrees to evaluate any such proposal by Repligen without delay, but the final decision shall be at the discretion of GEHC. 

  

	5.	Pricing of * 

  
 The Parties have agreed on the price conditions for * as set forth in Appendix 3 hereto. 
  

	6.	Supply * requirements 

  

	6.1.	Repligen agrees to develop a plan (“the * Plan”) to comply with best * practises according to those relevant portions of the guidelines published by * under the name * in
relation to Biotech rPA. For this purpose Repligen has adopted an implementation program including the milestones set forth in Appendix 4 (the “* Milestones”). 

  

	*	CONFIDENTIAL TREATMENT REQUESTED 

 Repligen will assume all the costs incurred in connection with implementing best * practises according to
the * and any costs for the * Plan in excess hereof relating to GEHC specific requirements shall be shared as agreed on a case by case basis. Repligen and GEHC shall agree in advance on any costs which GEHC shall assume in this respect. 

 
 GEHC shall have the right to carry out audits of the * Plan at Repligen
on or in close connection to each of the milestones dates in Appendix 4 and thereafter on a regular basis. If any of the * Milestone is not timely met, and following GEHC written notice thereof, Repligen shall use its best efforts to remedy such
failure as soon as possible and in each case within the remedy periods agreed in Appendix 4. If such a failure is not remedied within the agreed remedy periods then GEHC shall have the right to terminate this Amendment No. 1 with immediate effect
upon a second written notice, unless the failure is of no significant importance to the overall quality of the * Plan. If this Amendment No. 1 is terminated pursuant to this Section 6.1, Amendment No. 1 to the License Agreement shall also
immediately terminate and be of no further force or effect as specified in Section 2.4 of Amendment No. 1 to the License Agreement. 
  

	6.2.	If, for any reason, Repligen becomes unable to continue operations of its non-therapeutic protein A business relating to all or any of the Articles, it shall immediately inform GEHC
and shall offer to sell such business operations to GEHC at fair market value as agreed by good faith negotiations. Alternatively, in the event that Repligen wishes to sell said non-therapeutic protein A business to a third party, Repligen shall so
inform GEHC and, under confidentiality, shall disclose the identity of the prospective third party purchaser to GEHC. GEHC shall then have a period of 15 days to evaluate said third party purchaser for the purposes of: *. If, prior to the end of
said 15 day evaluation period, GEHC notifies Repligen that said third party purchaser is, in its view, *, Repligen shall further, under confidence, disclose the terms of the proposed sale. GEHC shall thereafter have 15 days to match the terms of the
proposed divestiture and acquire the business. If GEHC elects not to acquire the business under the terms offered, Repligen shall be free to complete the proposed divestiture with said third party purchaser but GEHC shall have no obligation
thereafter to assign the Supply Agreement. If, however, GEHC determines that said third party purchaser is * and/or does not otherwise notify Repligen during said 15 day evaluation period, GEHC hereby agrees to thereafter permit the assignment of
the Supply Agreement to said third party purchaser in the course of the sale. 

  

	7.	Steering Committee 

  
 In order to facilitate the collaboration and planning in relation to the Articles, the Parties shall form a steering committee for the purpose of
information exchange concerning, among others, the following topics: 
  

	 	a)	Long-term market development Protein A media 

  

	 	b)	On-going product development Protein A products 

  

	 	c)	Structural changes 

  

	*	CONFIDENTIAL TREATMENT REQUESTED 

	 	d)	Financial situation 

  

	 	e)	* 

  
 The steering committee shall meet 1-2 times per year and consist of 2 senior officers of each Party. 
  

	8.	Right to terminate in advance 

  
 In addition to its termination rights under Section 11(b) of the Supply Agreement, GEHC shall have the right to terminate the Supply Agreement with 12
months written notice if Repligen or any associated companies decides to * or if the control of Repligen’s non-therapeutic protein A business is acquired by a company which GEHC * the requirements of Section 4 a)-c) of this Amendment No. 1.

  

	9.	Prolongation of the Agreement 

  
 Section 11 (a) of the Supply Agreement shall be amended to read as follows: 
  
 “This Agreement will remain in effect from the date of signing up to and including December 31, 2010, and shall
thereafter be automatically extended for successive periods of 2 years unless terminated with 12 months written notice prior to any such anniversary date.” 
  

	10.	Amendment of price review clause 

  
 Section 4d of the Supply Agreement is amended to read in full as follows: 
  
 “On or before October 31 of each Contract Year, the parties will agree upon new, firm pricing for the subsequent
Contract Year based upon: i) any change in the United States Consumer Price Index as published at the end of the third quarter of the preceding calendar year or some other index or indices as may be mutually agreed upon by the parties and ii) any
other factors, *, etc. The new, firm prices will be made effective as of January 1 of the following Contract Year and will remain in effect throughout said Contract Year. In the event that the Parties cannot agree on any price changes, the prices
shall remain unchanged for the following Contract Year.” 
  

	11.	Miscellaneous 

  

	11.1.	Capitalized terms used in this Amendment No. 1 and not otherwise defined in this Amendment No. 1 shall have the meanings defined in the Supply Agreement. 

 

	11.2.	Except as expressly amended herein, all terms and conditions of the Supply Agreement are hereby ratified and confirmed and shall remain in full force and effect.

  

	*	CONFIDENTIAL TREATMENT REQUESTED 

	11.3.	This Amendment No. 1 shall be effective as from the Amendment Date. The term Supply Agreement as used in the Supply Agreement shall from and after the Amendment Date be deemed a
reference to the Supply Agreement as amended by this Amendment No. 1. 

  

	11.4.	References in this Amendment No. 1 or in the Supply Agreement to Biotech or to GEHC shall mean Amersham Biosciences AB. 

  
 This Amendment No. 1 may be executed in counterparts each of which shall be
deemed an original and all such counterparts shall constitute one and the same instrument The Parties have executed this Amendment No. 1 in two originals whereof the arties have taken one each. 
  

							
	 REPLIGEN CORPORATION
	 	 AMERSHAM BIOSCIENCES AB

				
	 By:
	 	 /s/ Walter Herlihy

	 	 By:
	 	 /s/ Peter Ehrenheim

	 Name:
	 	 Walter Herlihy
	 	 Name:
	 	 Peter Ehrenheim

	 Title:
	 	 President & CEO
	 	 Title:
	 	 President

  

	*	CONFIDENTIAL TREATMENT REQUESTED 

 Appendix 1 
  

Specifications - * 
  
 Terms of transportation 
  
 At or below - *. 
  
 Storage conditions

  
 *. 
  
 Shelf life 
  
 * from date of manufacturing. To be stated in the certificate of analysis. The limit is preliminary. The final shelf life is to be decided from stability studies.

  
 Mass 
  
 * 
  
 Description 
  
 * 
  
 * 
  

* 
  
 * 
  
 * 
  
 Requirements on properties 
  

									
	 Characteristic

	 	 Tolerance limit

	 	 Test method

	 	 Remark

	 1
	 	 *
	 	*	 	*	 	 
	 2
	 	 *
	 	*	 	*	 	 
	 3
	 	 *
	 	*	 	*	 	 
	 4
	 	 *
	 	*	 	*	 	 
	 5
	 	 *
	 	*	 	*	 	 
	 6
	 	 *
	 	*	 	*	 	 
	 7
	 	 *
	 	*	 	*	 	 

  

	*	CONFIDENTIAL TREATMENT REQUESTED 

 Appendix 2 
  

Tentative Technology Transfer Program concerning the manufacturing process for *. 
  
 1. Scope 
  
 GEHC has developed a manufacturing process for *. GEHC has also developed analysis methods to be used for characterization of the protein as well as analyze methods to be
used for in process analysis. 
  
 * 
  
 2. Technological goals 
  

	•	 	Expression level in production scale should be * 

  

	•	 	Overall yield for downstream processing from fermentor to formulated product of * 

  

	•	 	The implemented production method should meet the requirements of reasonable robustness to be suitable for process validation. 

  
 3. Specifications of * 
  
 See Appendix 1 
  
 4. Time schedule 
  
 Time schedule, including critical time and responsible persons, to be finalized 
  
 5. Milestones and Deliveries 
  
 MS1: * 
 -05 
  
 MS2: * 
 -05 
  
 MS3: * 
 -05 
  
 MS4: * 
 -05 
  
 MS5: * 
 -05 
  

	*	CONFIDENTIAL TREATMENT REQUESTED 

 MS6: * 
 -05 
  
 MS7: * 
 -05 
  
 6. Deliveries 
  
 From GEHC -Repligen 
  
 * 
  
 From Repligen -GEHC 
  
 * 
  
 All documents transferred between the parties shall be in the form of Controlled copies if
approved documents are transferred. In case a draft version is transferred version number, date and signature is mandatory. Acceptable ranges for all parameters, for critical parameters Proven Acceptable Ranges (PAR) is recommended for the purpose
of Manufacturing Formula and Process validation, shall be included in the methods transferred to Repligen. 
  
 7. Resources 
  

			
	 Allocated by GEHC
	 	 
		
	 Project leader:
	 	*
	 Fermentation:
	 	*
	 Recovery:
	 	*
	 Purification:
	 	*
	 Analysis:
	 	*
	 QA:
	 	*
		
	 Allocated by Repligen
	 	 
		
	 Project leader:
	 	*
	 Fermentation:
	 	*
	 Recovery:
	 	*
	 Purification:
	 	*
	 Analysis:
	 	*
	 QA:
	 	*
	 Production:
	 	*

  
 8. Contact persons 

 

			
	 REPLIGEN:
	  	 *

	 GEHC:
	  	 *

  
 9. Progress reports 

 
 Bi-weekly short written communications on project status and performance 
  

	*	CONFIDENTIAL TREATMENT REQUESTED 

 Appendix 3 
  

Price conditions – * 
  
 A. Prices 
  
 The following prices will apply after delivery of the agreed development and validation lots. 
  
 First * ever sold: * per gram 
  
 After the first * ever sold the following price table shall apply: 
  

			
	 Total quantity each year (gram)

	    	 Price per gram within the interval

	 Up to and incl. *
	    	*
	 *
	    	*
	 *
	    	*
	 *
	    	*
	 *
	    	*

  
 B. Price assumptions

  
 The above price conditions are based on (i) the process scale and
optimized design as disclosed to Repligen at the meeting September 15, 2004, (ii) * overall yield level, (iii) * expression level in the fermenter, (iv) similar raw material costs compared to Biotech rPA, (v) *, (vi) *. 
  
 Upon any material deviations, i e having any impact on the price of more than *, from the
assumptions set forth in this section occurring during the TTP and/or the * validation runs to follow the parties agree to adjust the prices correspondingly upon request of either party. Such request shall be made in writing not later than 30 days
after completion of all of the agreed validation lots. Upon such request the parties shall conduct negotiations in, good faith with the object to restore the economical balance between the parties. 
  
 C. Price changes 
  
 The prices set forth herein shall remain fixed until December 31, *, unless adjusted by mutual agreement in accordance with Section B in
this Appendix or subject to adjustment due to yield improvements resulting from major process changes according to Section 3.2 in the Amendment. 
  
 Following December 31, *, the parties shall review the price conditions on an annual basis in accordance with Section 4 d) in the Agreement as amended. 
  

	*	CONFIDENTIAL TREATMENT REQUESTED 

 Appendix 4 
  

Implementation Plan – * 
  

									
	 Milestone

	  	Milestone definition

	  	Acceptance criteria

	  	Last date of
completion

	  	Remedy period

	 1
	  	*	  	*	  	*	  	30 days
	 2
	  	*	  	*	  	*	  	30 days
	 3
	  	*	  	*	  	*	  	30 days
	 4
	  	*	  	*	  	*	  	30 days
	 5
	  	*	  	*	  	*	  	30 days

  

	*	CONFIDENTIAL TREATMENT REQUESTEDAmended & Restated 2001 Stock Option Plan, Form of Incentive Stock Option Agmt

 Exhibit 10.14 
  
 REPLIGEN CORPORATION 
  
 Incentive Stock Option Agreement 
  
 Repligen Corporation, a Delaware corporation (the “Company”), hereby grants as of the
                     day of
                     to
                     (the “Employee”), an option to purchase a maximum of
             shares (the “Option Shares”) of its Common Stock, par value $.01 per share (“Common Stock”), at the price of
$             per share, on the following terms and conditions: 
  
 1. Grant Under 2001 Repligen Corporation Stock Option Plan. This option is granted pursuant to and is governed by the 2001 Repligen Corporation
Stock Option Plan (the “Plan”) and, unless the context otherwise requires, terms used herein shall have the same meaning as in the Plan. Determinations made in connection with this option pursuant to the Plan shall be governed by the Plan
as it exists on this date. 
  
 2. Grant as Incentive Stock
Option; Other Options. This option is intended to qualify as an incentive stock option under Section 422 of the Internal Revenue Code of 1986, as amended, and the regulations thereunder (the “Code”). This option is in addition to any
other options heretofore or hereafter granted to the Employee by the Company or any subsidiary (as defined in the Plan), but a duplicate original of this instrument shall not effect the grant of another option. 
  
 3. Vesting of Option if Employment Continues. If the Employee has
continued to be employed by the Company or any subsidiary through the following dates, the Employee may exercise this option for the number of shares of Common Stock set opposite the applicable vesting date: 
  

			
	The date that is:	  	 
		
	One year but less than	  	             shares
	two years from the date hereof	  	 
		
	Two years but less than	  	an additional
	three years from the date hereof	  	             shares
		
	Three years but less than	  	an additional
	four years from the date hereof	  	             shares
		
	Four years but less than	  	an additional
	five years from the date hereof	  	             shares
		
	Five years or more	  	an additional
	from the date hereof	  	             shares

  
 Notwithstanding the foregoing, in
accordance with and subject to the provisions of the Plan, the Committee may, in its discretion, accelerate the date that any installment of this option becomes exercisable. The foregoing rights are cumulative and (subject to Sections 4 or 5 hereof
if the Employee ceases to be employed by the Company and all subsidiaries) may be exercised on or before the date which is ten years from the date this option is granted. 

 4. Termination of Employment. 
  
 (a) Termination Other Than for Cause: If the Employee ceases to be employed by the Company and all subsidiaries, other than
by reason of death or disability as defined in Section 5 or termination for Cause as defined in Section 4(c), no further installments of this option shall become exercisable, and this option shall terminate (and may no longer be exercised) after the
passage of three months from the Employee’s last day of employment, but in no event later than the scheduled expiration date. In such a case, the Employee’s only rights hereunder shall be those which are properly exercised before the
termination of this option. 
  
 (b) Termination for Cause: If the
employment of the Employee is terminated for Cause (as defined in Section 4(c)), no further installments of this option shall become exercisable, and this option shall terminate (and may no longer be exercised) after the passage of seven days from
the Employee’s last day of employment, but in no event later than the scheduled expiration date. In such a case, the Employee’s only rights hereunder shall be those which are properly exercised before the termination of this option.

  
 (c) Definition of Cause: “Cause” shall mean conduct
involving one or more of the following: (i) the substantial and continuing failure of the Employee, after notice thereof, to render services to the Company or any subsidiary in accordance with the terms or requirements of his or her employment; (ii)
disloyalty, gross negligence, willful misconduct, dishonesty or breach of fiduciary duty to the Company or any subsidiary; (iii) the commission of an act of embezzlement or fraud; (iv) deliberate disregard of the rules or policies of the Company or
any subsidiary or breach of an employment or other agreement with the Company or any subsidiary which results in direct or indirect loss, damage or injury to the Company or any subsidiary; (v) the unauthorized disclosure of any trade secret or
confidential information of the Company or any subsidiary; or (vi) the commission of an act which constitutes unfair competition with the Company or any subsidiary or which induces any customer or supplier to breach a contract with the Company or
any subsidiary. 
  
 5. Death; Disability. 
  
 (a) Death: If the Employee dies while in the employ of the Company or any
subsidiary or within three months after the termination of such Employee’s employment (or one year in the case of the termination of employment of an option holder who is disabled (as provided in the Plan), this option may be exercised, to the
extent otherwise exercisable on the date of his or her death, by the Employee’s estate, personal representative or beneficiary to whom this option has been assigned pursuant to Section 10, at any time within two years after the date of death,
but not later than the scheduled expiration date. 
  
 (b)
Disability: If the Employee ceases to be employed by the Company and all subsidiaries by reason of his or her disability (as defined in the Plan), this option may be exercised, to the extent otherwise exercisable on the date of the termination of
his or her employment, at any time within one year after such termination, but not later than the scheduled expiration date. 
  
 (c) Effect of Termination: At the expiration of the two-year period provided in paragraph (a) or one-year period provided in paragraph (b) of this Section
5 or the scheduled expiration date, whichever is the earlier, this option shall terminate (and shall no longer be exercisable) and the only rights hereunder shall be those as to which the option was properly exercised before such termination.

  
 6. Partial Exercise. This option may be exercised in
part at any time and from time to time within the above limits, except that this option may not be exercised for a fraction of a share unless such exercise is with respect to the final installment of stock subject to this option and cash in lieu of
a fractional share must be paid, in accordance with the Plan, to permit the Employee to 

 exercise completely such final installment. Any fractional share with respect to which an installment of this option
cannot be exercised because of the limitation contained in the preceding sentence shall remain subject to this option and shall be available for later purchase by the Employee in accordance with the terms hereof. 
  
 7. Payment of Price. 
  
 (a) The purchase price shall be paid in the following manner: 
  
 (i) in cash or by check; 
  
 (ii) subject to paragraph 7(b) below, if the Common Stock is then traded on
a national securities exchange or on the Nasdaq National Market (or successor trading system), by delivery of shares of the Common Stock having a fair market value equal as of the date of exercise to the purchase price; or 
  
 (iii) by any combination of the foregoing. 
  
 In the case of paragraph (ii) above, fair market value as of the date of
exercise shall be determined as of the last business day for which such prices or quotes are available prior to the date of exercise and shall mean (i) the last reported sale price (on that date) of the Common Stock on the principal national
securities exchange on which the Common Stock is traded, if the Common Stock is then traded on a national securities exchange; or (ii) the last reported sale price (on that date) of the Common Stock on the Nasdaq National Market (or successor
trading system), if the Common Stock is not then traded on a national securities exchange. 
  
 (b) Limitations on Payment by Delivery of Common Stock: If the Employee delivers Common Stock held by the Employee (“Old Stock”) to the Company in full or partial payment of the option price, and the Old
Stock so delivered is subject to restrictions or limitations imposed by agreement between the Employee and the Company, an equivalent number of Option Shares shall be subject to all restrictions and limitations applicable to the Old Stock to the
extent that the Employee paid for the Option Shares by delivery of Old Stock, in addition to any restrictions or limitations imposed by this Agreement. Notwithstanding the foregoing, the Employee may not pay any part of the purchase price hereof by
transferring Common Stock to the Company unless such Common Stock has been owned by the Employee free of any substantial risk of forfeiture for at least six months. 
  
 8. Restrictions on Resale. Until registered under the Securities Act of 1933, as amended (the “Securities
Act”), Option Shares will be of an illiquid nature and will be deemed to be “restricted securities” for purposes of the Securities Act. Accordingly, such shares must be sold in compliance with the registration requirements of the
Securities Act or an exemption therefrom. Unless the Option Shares have been registered under the Securities Act, each certificate evidencing any of the Option Shares shall bear a legend substantially as follows: 
  
 “The shares represented by this certificate are subject to restrictions
on transfer and may not be sold, exchanged, transferred, pledged, hypothecated or otherwise disposed of except in accordance with and subject to all the terms and conditions of a certain Incentive Stock Option Agreement, a copy of which the Company
will furnish to the holder of this certificate upon request and without charge.” 
  
 9. Method of Exercising Option. Subject to the terms and conditions of this Agreement, this option may be exercised by written notice to the Company at its principal executive office, or to such transfer agent
as the Company shall designate. Such notice shall state the election to 

 exercise this option and the number of Option Shares for which it is being exercised and shall be signed by the person or
persons so exercising this option. Such notice shall be accompanied by payment of the full purchase price of such shares, and the Company shall deliver a certificate or certificates representing such shares as soon as practicable after the notice
shall be received. Such certificate or certificates shall be registered in the name of the person or persons so exercising this option (or, if this option shall be exercised by the Employee and if the Employee shall so request in the notice
exercising this option, shall be registered in the name of the Employee and another person jointly, with right of survivorship). In the event this option shall be exercised, pursuant to Section 5 hereof, by any person or persons other than the
Employee, such notice shall be accompanied by appropriate proof of the right of such person or persons to exercise this option. 
  
 10. Option Not Transferable. This option is not transferable or assignable except by will or by the laws of descent and distribution. During the
Employee’s lifetime only the Employee can exercise this option. 
  
 11. No Obligation to Exercise Option. The grant and acceptance of this option imposes no obligation on the Employee to exercise it. 
  
 12. No Obligation to Continue Employment. Neither the Plan, this Agreement, nor the grant of this option imposes any obligation on the Company or
any subsidiary to continue the Employee in employment. 
  
 13.
No Rights as Stockholder until Exercise. The Employee shall have no rights as a stockholder with respect to the Option Shares until such time as the Employee has exercised this option by delivering a notice of exercise and has paid in full the
purchase price for the shares so exercised in accordance with Section 9. Except as is expressly provided in the Plan with respect to certain changes in the capitalization of the Company, no adjustment shall be made for dividends or similar rights
for which the record date is prior to such date of exercise. 
  
 14. Capital Changes and Business Successions. The Plan contains provisions covering the treatment of options in a number of contingencies such as stock splits and mergers. Provisions in the Plan for adjustment with respect to stock
subject to options and the related provisions with respect to successors to the business of the Company are hereby made applicable hereunder and are incorporated herein by reference. 
  
 15. Withholding Taxes. If the Company or any subsidiary in its discretion determines that it is obligated to withhold
any tax in connection with the exercise of this option, or in connection with the transfer of, or the lapse of restrictions on, any Common Stock or other property acquired pursuant to this option, the Employee hereby agrees that the Company or any
subsidiary may withhold from the Employee’s wages or other remuneration the appropriate amount of tax. At the discretion of the Company or any subsidiary, the amount required to be withheld may be withheld in cash from such wages or other
remuneration or in kind from the Common Stock or other property otherwise deliverable to the Employee on exercise of this option. The Employee further agrees that, if the Company or any subsidiary does not withhold an amount from the Employee’s
wages or other remuneration sufficient to satisfy the withholding obligation of the Company or subsidiary, the Employee will make reimbursement on demand, in cash, for the amount underwithheld. 
  
 16. Early Disposition. The Employee agrees to notify the Company in
writing immediately after the Employee transfers any Option Shares, if such transfer occurs on or before the later of (a) the date that is two years after the date of this Agreement or (b) the date that is one year after the date on which the
Employee acquired such Option Shares. The Employee also agrees to provide the Company with any information concerning any such transfer required by the Company for tax purposes. 

 17. Arbitration. Any dispute, controversy, or claim arising out of, in connection with, or
relating to the performance of this Agreement or its termination shall be settled by arbitration in the Commonwealth of Massachusetts, pursuant to the rules then obtaining of the American Arbitration Association. Any award shall be final, binding
and conclusive upon the parties and a judgment rendered thereon may be entered in any court having jurisdiction thereof. 
  
 18. Provision of Documentation to Employee. By signing this Agreement the Employee acknowledges receipt of a copy of this Agreement and a copy of
the Plan. 
  
 19. Miscellaneous. 
  
 (a) Notices: All notices hereunder shall be in writing and shall be deemed
given when sent by certified or registered mail, postage prepaid, return receipt requested, to the address set forth below. The addresses for such notices may be changed from time to time by written notice given in the manner provided for herein.

  
 (b) Entire Agreement; Modification: This Agreement constitutes
the entire agreement between the parties relative to the subject matter hereof, and supersedes all proposals, written or oral, and all other communications between the parties relating to the subject matter of this Agreement. This Agreement may be
modified, amended or rescinded only by a written agreement executed by both parties. 
  
 (c) Severability: The invalidity, illegality or unenforceability of any provision of this Agreement shall in no way affect the validity, legality or enforceability of any other provision. 
  
 (d) Successors and Assigns: This Agreement shall be binding upon and inure to
the benefit of the parties hereto and their respective successors and assigns, subject to the limitations set forth in Section 10 hereof. 
  
 (e) Governing Law: This Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware, without giving effect to the
principles of the conflicts of laws thereof. The preceding choice of law provision shall apply to all claims, under any theory whatsoever, arising out of the relationship of the parties contemplated herein. 
  
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 IN WITNESS WHEREOF, the Company and the Employee have caused this instrument to be executed as of the
date first above written. 
  

					
	 	 	Repligen Corporation
	
	 	41 Seyon Street
	Employee	 	Waltham, MA 02453
			
	  

	 	By:	 	  

	Print Name of Employee	 	 	 	Walter C. Herlihy
	 	 	 	 	President & CEO
	  

	 	 	 	 
	Street Address	 	 	 	 
	  
  

	 	 	 	 
	City     State     Zip Code

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}]]